According to a new report LAMEA Autoimmune Disease Therapeutics Market, published by KBV research, the LAMEA Autoimmune Disease Therapeutics Market would witness market growth of 5.38% CAGR during the forecast period (2019-2025).
The Brazil market dominated the LAMEA Hospital Pharmacy Market by Country in 2018, growing at a CAGR of 4.5 % during the forecast period. The Argentina market is expected to witness a CAGR of 6.1% during (2019-2025). Additionally, The UAE market is expected to witness a CAGR of 4.9% during (2019-2025).
The Rheumatic Disease market dominated the LAMEA Autoimmune Disease Therapeutics Market by Indication in 2018, growing at a CAGR of 5.5 % during the forecast period. The Multiple Sclerosis market is expected to witness a CAGR of 5.6% during (2019-2025).
The Anti-Inflammatory market dominated the Saudi Arabia Autoimmune Disease Therapeutics Market by Drug Class in 2018, thereby, achieving a market value of $813.1 million by 2025, growing at a CAGR of 5.8 % during the forecast period. The Anti-Hyperglycemics market is expected to witness a CAGR of 5.9% during (2019-2025).
Full Report: https://www.kbvresearch.com/lamea-autoimmune-disease-therapeutics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of ABBOTT Laboratories, Bio-Rad Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, AbbVie, Inc., Amgen, Inc. and Novartis AG.
By Indication
By Drug Class
By Distribution Channel
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
